9IA3 | pdb_00009ia3

Bc8.108 Fab bound to preS2 peptide


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.11 Å
  • R-Value Free: 
    0.187 (Depositor), 0.187 (DCC) 
  • R-Value Work: 
    0.173 (Depositor), 0.173 (DCC) 
  • R-Value Observed: 
    0.173 (Depositor) 

Starting Model: in silico
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9IA3

This is version 1.1 of the entry. See complete history

Literature

In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus.

Beretta, M.Mechaly, A.Planchais, C.Haouz, A.Caillet-Saguy, C.Szerman, N.Aronthippaitoon, Y.Ungeheuer, M.N.Pol, S.Gaudy-Graffin, C.Sureau, C.Bourgine, M.Mouquet, H.

(2025) Cell Rep 44: 116705-116705

  • DOI: https://doi.org/10.1016/j.celrep.2025.116705
  • Primary Citation Related Structures: 
    9IA3, 9IA4, 9IAT

  • PubMed Abstract: 

    Antibodies targeting the hepatitis B virus (HBV) surface antigens (HBsAg) are essential for the prevention and control of HBV infection, yet their molecular and functional properties remain incompletely understood. Here, we characterize HBV seroconverter-derived human memory B cell monoclonal antibodies targeting preS1, preS2, and small (S) HBsAg regions. We find that broadly reactive anti-preS2 antibodies neutralize HBV and exert Fc-dependent effector functions that significantly contribute to their in vivo antiviral activity in HBV-carrier mice. Mapping and structural analysis reveal that they target an immunodominant epitope at the N terminus of preS2. Combining anti-preS2 and anti-S broadly neutralizing antibodies (bNAbs) isolated from the same donor profoundly and durably reduces antigenemia and viremia in HBV-carrier mice. These findings underscore the antiviral potential of anti-preS2 antibodies, particularly when combined with potent anti-S bNAbs, emphasizing their relevance for enhancing HBV vaccine efficacy and advancing immunotherapy development.


  • Organizational Affiliation
    • Institut Pasteur, Université Paris Cité, Humoral Immunology Unit, 75015 Paris, France.

Macromolecule Content 

  • Total Structure Weight: 50.67 kDa 
  • Atom Count: 4,321 
  • Modeled Residue Count: 466 
  • Deposited Residue Count: 466 
  • Unique protein chains: 3

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Fab Bc8.108 light chain215Homo sapiensMutation(s): 0 
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
Fab Bc8.108 heavy chain228Homo sapiensMutation(s): 0 
Find similar proteins by:  Sequence   |   3D Structure  
Entity ID: 3
MoleculeChains  Sequence LengthOrganismDetailsImage
Large S proteinC [auth E]23Hepatitis B virusMutation(s): 0 
UniProt
Find proteins for B2Y6K4 (Hepatitis B virus)
Explore B2Y6K4 
Go to UniProtKB:  B2Y6K4
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupB2Y6K4
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.11 Å
  • R-Value Free:  0.187 (Depositor), 0.187 (DCC) 
  • R-Value Work:  0.173 (Depositor), 0.173 (DCC) 
  • R-Value Observed: 0.173 (Depositor) 
Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 82.198α = 90
b = 65.131β = 106.85
c = 100.635γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
autoPROCdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Pasteur InstituteFrance--

Revision History  (Full details and data files)

  • Version 1.0: 2025-11-26
    Type: Initial release
  • Version 1.1: 2026-05-06
    Changes: Database references